Author

M. J. Steinbaugh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Organism:C. elegans· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:development & morphogenesis· 1 Organism:human· 1

Frequent Co-Authors

A. Bommi-Reddy· 1 shared A. Conery· 1 shared A. Hingway· 1 shared D. N. Mayhew· 1 shared E. Terzo· 1 shared F. Zhu· 1 shared J. E. Wilson· 1 shared J. I. Castillo-Quan· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bommi-Reddy

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An anti-steatosis response regulated by oleic acid through lipid droplet-mediated ERAD enhancement

J. I. Castillo-Quan, M. J. Steinbaugh, L. P. Fernandez-Cardenas, N. K. Pohl, Z. Wu, F. Zhu, N. Moroz, V. Teixeira, M. S. Bland, N. J. Lehrbach, L. E. M. Mazzeo, M. Teufl, T. K. Blackwell

This study shows oleic acid enhances ERAD via lipid droplets to increase SKN-1A levels, reducing steatosis and promoting longevity in C. elegans.

bioRxiv · Jun 15, 2022 · PreprintCell Biology

CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells

A. Conery, A. Bommi-Reddy, S. Park-Chouinard, D. N. Mayhew, E. Terzo, A. Hingway, M. J. Steinbaugh, J. E. Wilson, R. J. Sims

This study shows that inhibiting CREBBP/EP300 acetyltransferase suppresses ER+ breast cancer growth by disrupting FOXA1-bound enhancers, offering a new therapeutic strategy.

bioRxiv · Dec 26, 2021Cancer Biology